The prognostic value of POD24 in relapsed/refractory follicular lymphoma-A SCHOLAR-5 analysis Journal Article


Authors: Limbrick-Oldfield, E. H.; Kanters, S.; Ray, M. D.; Best, T.; Palivela, M.; Beygi, S.; Patel, A. R.; Gribben, J. G.; Ghione, P.
Article Title: The prognostic value of POD24 in relapsed/refractory follicular lymphoma-A SCHOLAR-5 analysis
Abstract: IntroductionFollicular lymphoma (FL) has a heterogeneous prognosis. Progression within 24 months of starting front-line therapy (POD24) is prognostic of overall survival (OS). Despite its prognostic value in early lines, the role of POD24 in relapsed/refractory (R/R) patients initiating later lines of therapy (LoTs) is unknown.MethodsWe analyzed the SCHOLAR-5 real-world cohort to investigate whether POD24 is prognostic in patients with R/R FL initiating >= 3rd LoT.ResultsAmong the 128 SCHOLAR-5 patients, 34 patients experienced POD24. POD24 patients received their >= 3 LoT after a shorter time compared with non-POD24 patients (median 42.0 months [range: 8.8-17.8] vs. 109.9 months [range: 29.6-310.2]). Using a time-dependent multivariate Cox model, POD24 was predictive of shorter OS from initiation of >= 3rd LoT with a hazard ratio (HR) of 2.44 (95% confidence interval [CI]: 1.20-4.96). For progression-free survival, using a multivariate repeated-measures Cox model, the effect was similar but not statistically significant (HR: 1.45; 95% CI: 0.94-2.11).ConclusionThis study demonstrates that among patients with R/R FL initiating a >= 3rd LoT, POD24 patients reach these LoTs sooner after diagnosis and POD24 remains prognostic of subsequent OS. This suggests that POD24 status can inform clinical decision making in this population.
Keywords: survival; outcomes; follicular lymphoma; non-hodgkin lymphoma; high-risk; prognostic; end-point; treatment patterns; pod24; real world
Journal Title: eJHaem
Volume: 6
Issue: 1
ISSN: 2688-6146
Publisher: Wiley Blackwell  
Date Published: 2025-02-01
Start Page: e1104
Language: English
ACCESSION: WOS:001414521100001
DOI: 10.1002/jha2.1104
PROVIDER: wos
PMCID: PMC11800366
PUBMED: 39917356
Notes: Article -- e1104 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Paola Ghione
    74 Ghione